Abstract| Volume 116, P84-85, December 2022

P048Risk of uterine rupture in second-trimester medication abortions using mifepristone and misoprostol after cesarean section birth: A systematic review and meta-analysis

      This paper is only available as a PDF. To read, Please Download here.


      To assess the risk of uterine rupture when using current mifepristone and misoprostol regimens for second-trimester abortion among those who had a prior cesarean section birth.


      After prospectively registering on PROSPERO (CRD42022302626), we systematically searched PubMed, EMBASE, POPLINE,, and Cochrane Library using search terms “second-trimester,” “induction,” “mifepristone,” and “abortion” from inception until January 2022. We limited our sample to studies including pregnancies of 14–28 weeks’ gestation, studies with a mixed cohort with and without uterine scar, and studies available in English. We excluded case reports and narrative reviews. Two authors independently reviewed studies. Absolute risk with binomial confidence intervals was calculated from pooled data. Using R software, total risk difference was estimated by the Mantel-Haenszel random effects method without continuity correction. For studies with zero events, a continuity correction of 0.5 was applied in the forest plot for individual risk differences. Statistical heterogeneity was assessed with Higgins I2 statistics. Funnel plot assessed for publication bias.


      Of 198 articles identified, 19 met inclusion criteria: seven randomized trials (n=923) and 12 observational studies (n=2,589). Uterine rupture risk with prior cesarean birth was 1.8% (7/385) (95% CI, 0.7–3.7) and without was 0.1% (2/3,127) (95% CI, 0.0–0.2). The risk difference was 0.01 (95% CI, 0.00–0.03; I2=0%). Minor funnel plot asymmetry demonstrated low evidence of publication bias.


      Uterine rupture during second-trimester abortion is a rare event but risk does appear to increase among those with a prior cesarean section birth. In the context of patient-centered counseling, this may be acceptable to both patients and providers.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect